Joint capsule

New Study from HSS Reveals Minimally Invasive Procedure Can Delay Arthritis in Select Patients with Hip Impingement

Retrieved on: 
torsdag, april 18, 2024
Pain, Mechanics, FAI, HSS, Hip, Sports medicine, Hospital for Special Surgery, Hospital, Risk, Osteoarthritis, Femoroacetabular impingement, American Journal, Publishing, Research design, MD, Arthroscopy, Hip pain, Research, Arthritis, Patient, Paper, MBA, Philip, FRCS, Joint capsule, Friction, Arthroplasty

NEW YORK, April 18, 2024 /PRNewswire/ -- A new study by surgeon-scientists at Hospital for Special Surgery (HSS) found that 25% of patients with hip impingement who underwent modern arthroscopy for their condition experienced a delay in the natural progression of osteoarthritis. The retrospective study, published online on March 8, 2024, in The American Journal of Sports Medicine, is the first to link hip arthroscopy with a reduced risk of developing hip arthritis over the long term.

Key Points: 
  • Hip impingement occurs when the bones of the hip joint are not shaped properly, causing them to rub against one another.
  • Prior studies have shown that 85-90% of patients with hip impingement who undergo modern arthroscopy return to their usual activity level.
  • "By contrast, we studied the effect of modern arthroscopic methods by comparing the degree of arthritis in each patient's operative hip versus their nonoperative hip.
  • For ideal candidates, the evidence shows that hip arthroscopy may delay or prevent arthritis for one in four patients.

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Retrieved on: 
tisdag, september 12, 2023
KRAS, Nanoparticle, Rhinitis, Marketing, Synovitis, Heqet, Allergic rhinitis, RNA, MBA, Doctor of Philosophy, Preprint, Patent, Patient, NF-κB, MITES, AVS, DNMT3B, Rheumatoid arthritis, Joint capsule, Therapy, Myocardial infarction, Research, Small RNA, Regeneration, Sneeze, Washington University School of Law, Neoplasm, Nasal spray, FDA, Vertigo, IND, Safety, Volunteering, SAR, Altamira, Cell, IP, Immunotherapy, Messenger, NASAR, Nasal congestion, CHF, Osteoarthritis Research Society International, Rhinorrhea, Q&A, SARS-CoV-2, Infection, Clinical trial, Pollen, Inflammation, ANCOVA, OTC, Mouse, Washington University School of Medicine, Vaccine, Pharmaceutical industry, Cryptocurrency, BPPV, St. Louis

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.

Key Points: 
  • Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.
  • ET
    Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.
  • Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022.
  • ET to discuss its business update and first half 2023 results.

Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation

Retrieved on: 
tisdag, april 25, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Acceleration, Joint capsule, GALA, Amaravati seed capital road, IMCB, Agency for Science, Technology and Research, Arthritis, Institute of Molecular and Cell Biology, Neoplasm, SEEDS, Connective tissue, Biologic, The Golden Ticket, Toxicity, Antibody, Albatroz-class patrol boat, Duke–NUS Medical School, Cell biology, Patient, Extracellular matrix, Golden Ticket, CSCB, Growth, Therapy, Recurrence, Glycosylation, Metastasis, Pharmaceutical industry, Vaccine, Amgen, Cancer

The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.

Key Points: 
  • The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.
  • Cancer that has metastasized, spreading to other parts of the body, is notoriously difficult to treat and accounts for most cancer deaths.
  • Albatroz has secured exclusive rights on a highly specific and novel target that blocks tumor growth and recurrence, including a range of therapeutic antibodies that inhibit this target.
  • Activation of the target occurs specifically in tumors and arthritic synovial membranes, connective tissue that lines the joint capsule.

Arthrosamid By Top Expert Prof. Lee Debuts at London's 108 Harley Street Clinic

Retrieved on: 
onsdag, september 7, 2022
Osteoarthritis, Pain, Knee, PRP, Pressure, Sport, Harley Street, Injection, Cartilage, Quality of life, ACL, Joint, Plasma, Hyaluronic acid, Joint capsule, MSK, Patient, Pharmaceutical industry, Dentistry

A renowned 108 Harley Street doctor specialising in musculoskeletal injuries announces an expansion of his Arthrosamid injection treatments for clients suffering from tissue degeneration in the knee.

Key Points: 
  • London, United Kingdom--(Newsfile Corp. - September 7, 2022) - 108 Harley Street's Professor Paul Lee has launched a non-biodegradable hydrogel-based rehabilitative program.
  • Arthrosamid By Top Expert Prof. Lee Debuts at London's 108 Harley Street Clinic
    To view an enhanced version of this graphic, please visit:
    The announcement affirms Professor Lee's reputation as a leading specialist in pain relief and deep tissue therapy for osteoarthritis of the knee - a debilitating condition that most commonly affects people over 40 years of age.
  • 108 Harley Street's new hydrogel treatment addresses the damage caused to knee cartilage.
  • With the launch of Arthrosamid injections, Professor Lee and 108 Harley Street continue to pioneer new treatment approaches for osteoarthritis sufferers across the UK.

Knee Arthrosamid Injections By Prof. Lee Introduced At London Cartilage Clinic

Retrieved on: 
torsdag, september 1, 2022
Connective tissue, Inflammation, Technology, Platelet-rich plasma, Knee, Injection, Professor, Synovial fluid, Board, Contraindication, Diagnosis, Viscosity, Water, Surgeon, Movement, Hyaluronic acid, Joint capsule, Patient, Medical imaging

Harley Street, UK - London Cartilage Clinic, founded and led by Prof. Paul Lee, introduces its latest treatment for knee osteoarthritis. Arthrosamid(R) is an intra-articular polyacrylamide hydrogel injection (iPAAG) that offers longer-lasting relief than traditional hyaluronan injections.

Key Points: 
  • London, United Kingdom--(Newsfile Corp. - September 1, 2022) - The new treatment offered at London Cartilage Clinic is an affordable alternative to currently available therapies.
  • Knee Arthrosamid Injections By Prof. Lee Introduced At London Cartilage Clinic
    To view an enhanced version of this graphic, please visit:
    As part of the latest therapy performed at London Cartilage Clinic, the doctors inject the non-biodegradable hydrogel into the patient's knee.
  • Arthrosamid integrates into the soft synovial tissue in the joint capsule, offering longer-lasting pain relief.
  • The clinic refers to results from several clinical trials involving the use of Arthrosamid that point to little to no side effects from the knee injection, granting it an overall satisfactory safety profile.

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

Retrieved on: 
torsdag, augusti 4, 2022
Metabolism, Diagnosis, Pressure, Shionogi, Marketing, Transience, Synovial membrane, Neck, Quality of life, Osteoarthritis, Joint capsule, Infection, TRPV1, Patient, Medicine, OA, Pain, Pain management, Knee, Tissue, Common, RTX, Arthralgia, Health, Genetics, Physical examination, Arthropathy, Ageing, Ligament, Female, Joint, Pharmaceutical industry, Dentistry, Phase

Shionogi obtained the exclusive rights to commercialise Grnenthal's asset in Japan for pain associated with osteoarthritis of the knee.

Key Points: 
  • Shionogi obtained the exclusive rights to commercialise Grnenthal's asset in Japan for pain associated with osteoarthritis of the knee.
  • RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis.
  • Thereof, Shionogi will pay $ 75 million upon signature, and further milestone payments of $ 70 million prior to regulatory approval.
  • RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

Retrieved on: 
torsdag, augusti 4, 2022
Metabolism, Diagnosis, Pressure, Shionogi, Marketing, Transience, Synovial membrane, Neck, Quality of life, Osteoarthritis, Joint capsule, Infection, TRPV1, Patient, Medicine, OA, Pain, Pain management, Knee, Tissue, Common, RTX, Arthralgia, Health, Genetics, Physical examination, Arthropathy, Ageing, Ligament, Female, Joint, Pharmaceutical industry, Dentistry, Phase

Shionogi obtained the exclusive rights to commercialise Grnenthal's asset in Japan for pain associated with osteoarthritis of the knee.

Key Points: 
  • Shionogi obtained the exclusive rights to commercialise Grnenthal's asset in Japan for pain associated with osteoarthritis of the knee.
  • RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis.
  • Thereof, Shionogi will pay $ 75 million upon signature, and further milestone payments of $ 70 million prior to regulatory approval.
  • RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.

Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives

Retrieved on: 
fredag, april 8, 2022
Innovation, Company, LinkedIn, RCT, Radiation, Patient, Skin, Necrotizing fasciitis, Sal DiDomenico, Standard of care, Tissue, PMID, Evidence-based medicine, LLC, Twitter, Nasdaq, Joint capsule, GLOBE, Physician, Medicare, NEXUS, FDA, Wound healing, Pharmaceutical industry

Bioventus TheraSkin is a cellular and tissue-based treatment for difficult to heal chronic wounds and this expanded coverage adds more than 17 million medical lives to the existing coverage.

Key Points: 
  • Bioventus TheraSkin is a cellular and tissue-based treatment for difficult to heal chronic wounds and this expanded coverage adds more than 17 million medical lives to the existing coverage.
  • This recent publication further supplements the 13 previous published articles supporting wound treatment with TheraSkin.
  • Bioventus and the Bioventus logo, are registered trademarks of Bioventus LLC.
  • BoneScalpel, SonaStar, SonicOne and neXus are registered trademarks of Misonix, Inc. TheraSkin is a registered trademark of Soluble Systems, LLC.

Grünenthal and NovaQuest Enter Agreement to Advance the Resiniferatoxin Global Phase III Program in Osteoarthritis

Retrieved on: 
tisdag, mars 29, 2022
General Health, Finance, Banking, Health, Professional Services, Metabolism, Human, Osteoarthritis, Investment, Marketing, Diagnosis, Neck, III, Growth, Multimedia, Physical examination, Genetics, Common, Arthralgia, Pressure, Synovial membrane, Ageing, Specialization, Tissue, Pain, Pain management, Joint, Arthropathy, RTX, Transience, MD, Quality of life, Safety, OA, TRPV1, Knee, Joint capsule, Animal, Patient, Ligament, Phase, Pharmaceutical industry, Dentistry, EU, NOVAQUEST, RTX, OSTEOARTHRITIS, GRüNENTHAL

Grnenthal and NovaQuest announced today that they have entered an agreement to advance the global clinical Phase III programme of Grnenthal's asset resiniferatoxin (RTX).

Key Points: 
  • Grnenthal and NovaQuest announced today that they have entered an agreement to advance the global clinical Phase III programme of Grnenthal's asset resiniferatoxin (RTX).
  • The Phase III trials will investigate the efficacy, safety and tolerability of RTX in patients with pain associated with osteoarthritis of the knee.
  • Under the terms of the agreement, NovaQuest will reimburse Grnenthals investments into the clinical phase III programme of RTX and share the clinical development and approval risks with Grnenthal.
  • RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with advanced knee osteoarthritis.

Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis

Retrieved on: 
tisdag, mars 29, 2022
Metabolism, Human, Osteoarthritis, Investment, Marketing, Diagnosis, Neck, III, Growth, Physical examination, Genetics, Common, Arthralgia, Pressure, Synovial membrane, Ageing, Research Triangle, Specialization, Tissue, Pain, Pain management, Joint, Arthropathy, RTX, Transience, MD, Quality of life, Safety, OA, TRPV1, Knee, Joint capsule, Animal, Patient, Ligament, Phase, Pharmaceutical industry, Dentistry, EU

AACHEN, Germany and RALEIGH, N.C., March 29, 2022 /PRNewswire/ --Grnenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grnenthal's asset resiniferatoxin (RTX).

Key Points: 
  • AACHEN, Germany and RALEIGH, N.C., March 29, 2022 /PRNewswire/ --Grnenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grnenthal's asset resiniferatoxin (RTX).
  • The Phase III trials will investigate the efficacy, safety and tolerability of RTX in patients with pain associated with osteoarthritis of the knee.
  • This agreement provides Grnenthal headroom for further investments in the execution of its growth strategy and the advancement of a promising pipeline into the clinic."
  • Under the terms of the agreement, NovaQuest will reimburse Grnenthal's investments into the clinical phase III programme of RTX and share the clinical development and approval risks with Grnenthal.